Show summary Hide summary
- Key CDC data: a dramatic uptick in resistant infections
- How these “nightmare bacteria” beat our best drugs
- Where infections occur and who is most vulnerable
- Treatment limits and clinical dilemmas
- Containment strategies in hospitals and care facilities
- Antimicrobial resistance: the broader public health emergency
- What clinicians and caregivers can do now
A recent CDC analysis warns that a group of highly drug-resistant bacteria has climbed sharply in U.S. hospitals over the past four years. The surge centers on strains that can deactivate last-resort antibiotics, creating tough-to-treat infections and narrowing treatment options for seriously ill patients.
Key CDC data: a dramatic uptick in resistant infections
The CDC-led report, published in Annals of Internal Medicine, tracked clinical cultures from 2019 to 2023 across surveillance networks in 29 states. It found a 69% rise in carbapenemase-producing carbapenem-resistant Enterobacterales, or CP-CRE. Within that group, infections tied to the New Delhi metallo-β-lactamase variant (NDM-CRE) jumped by 461%.
Eggs every day for months: simple check reveals shocking blood test result
Popular childhood food ingredient may raise adult anxiety: study
Earlier CDC estimates put the nationwide toll of CRE in 2020 at roughly 12,700 infections and about 1,100 deaths. The new figures suggest the problem is expanding and evolving.
How these “nightmare bacteria” beat our best drugs
Enterobacterales include common species such as E. coli and Klebsiella. When they become carbapenem-resistant (CRE), they no longer respond to carbapenems — powerful broad-spectrum antibiotics used as a last line of defense.
CP-CRE produce enzymes called carbapenemases. These enzymes break down carbapenem molecules, rendering the drugs ineffective. NDM-CRE carries a form of carbapenemase that can defeat even some newer agents developed for resistant infections.
Genes that hop between bacteria
NDM-CRE can transfer resistance genes to other bacterial strains and species. This gene-sharing accelerates the spread of resistance and complicates efforts to control outbreaks.
Where infections occur and who is most vulnerable
These infections are primarily a healthcare threat. The rise detected by the CDC is concentrated among hospitalized patients, not the general community.
- Highest-risk groups: people on ventilators
- patients with urinary or intravenous catheters
- those receiving prolonged antibiotic courses
- people with weakened immune systems
CP-CRE can infect different parts of the body. Presentation depends on the site:
- urinary tract infections
- pneumonia and respiratory infections
- bloodstream infections
- wound infections and, rarely, meningitis
Because symptoms mirror common infections, rapid detection and lab testing are critical to choose an effective therapy.
Treatment limits and clinical dilemmas
CP-CRE are resistant to most antibiotics. Clinicians must balance drug choice with patient factors such as kidney or liver function, allergies, and severity of illness.
Detecting the exact carbapenemase type helps tailor therapy, but options remain limited. That reality increases the risk of poor outcomes and places pressure on hospitals to use specialized diagnostics.
Containment strategies in hospitals and care facilities
Stopping CP-CRE spread requires coordinated infection control and surveillance. Key measures include:
- routine screening and rapid reporting of cases
- strict hand hygiene among staff, patients, and visitors
- cleaning and disinfection of surfaces and medical devices
- contact precautions for colonized or infected patients
- antimicrobial stewardship to limit unnecessary antibiotic use
Transmission commonly occurs via direct contact or contaminated equipment. Rare animal-to-human transmission has been documented, and people can carry CRE without symptoms, a process known as colonization.
Antimicrobial resistance: the broader public health emergency
Antimicrobial resistance (AMR) spans bacteria, viruses, fungi, and parasites that evolve to survive drugs meant to kill them. Experts call it a “silent pandemic” because it grows quietly while straining healthcare systems.
In the U.S., nearly 3 million AMR infections occur each year. Globally, estimates linked AMR to about 5 million deaths in 2019. A 2024 Lancet forecast warned that, by 2050, antibiotic-resistant bacterial infections could be associated with 39 million deaths cumulatively, with nearly 1.91 million deaths projected in that year alone.
To slow this trend, public health agencies and hospitals are expanding antimicrobial stewardship programs. These efforts aim to improve prescribing, protect effective drugs, and speed access to better diagnostics.
What clinicians and caregivers can do now
- Report and test early when resistant infection is suspected.
- Follow strict infection-control protocols in care settings.
- Use antibiotics only when medically necessary and with correct dosing.
- Prioritize handwashing and equipment sterilization.
- Educate caregivers of vulnerable people about prevention steps.
Public health experts emphasize vigilance in hospitals and long-term care facilities as the most effective way to curb further spread of these highly resistant organisms.
